Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Clinical trial NCT03781063 · COMPLETED

Trial details

NCT number: NCT03781063
Sponsor: Sermonix Pharmaceuticals Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Locally Advanced or Metastatic Breast Cancer

Start date: 2019-09-20
Primary completion: 2025-05-08
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.